Pancreatic Cancer Research

ResearcherYokohama City UniversityActive in the last 2 years

Toru Aoyama

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6803-3800; OpenAlex author ID A5007724809. Sources: OpenAlex.

Their work

Papers
25 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2014: 1 paper · 2015: 7 papers · 2016: 4 papers · 2017: 3 papers · 2018: 3 papers · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper

Papers 25

  1. Overexpression of Nuclear Factor of Activated T-cells (NFAT) Transcription Factors Drives Chemoresistance and Poor Outcomes in Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18186-9↗
  2. Clinical Impact of Preoperative Neutrophil-to-Lymphocyte Ratio in Surgical Patients With Pancreatic Cancer. First author DOI 10.21873/anticanres.16805↗
  3. Clinical Impact of Preoperative Prognostic Nutritional Index in Surgical Patients With Pancreatic Cancer Treated With Perioperative Adjuvant Chemotherapy. First author DOI 10.21873/anticanres.16970↗
  4. Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-insti… Co-author DOI 10.21873/invivo.11780↗
  5. The Impact of Intraoperative Blood Loss on the Survival of Patients With Stage II/III Pancreatic Cancer. First author DOI 10.21873/invivo.11931↗
  6. The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuva… Co-author DOI 10.4103/jcrt.jcrt_440_18↗
  7. The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection. First author DOI 10.7150/jca.28660↗
  8. The Lymph Node Ratio Is an Independent Prognostic Factor in Pancreatic Cancer Patients Who Receive Curative Resection Followed by Adjuvant Chemotherapy. Co-author DOI 10.21873/anticanres.12801↗
  9. Safety and feasibility of enhanced recovery after surgery in the patients underwent distal pancreatectomy for pancreatic cancer. Co-author DOI 10.4103/0973-1482.183186↗
  10. Survival and the prognosticators of peritoneal cytology-positive pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy. Co-author DOI 10.4103/0973-1482.194927↗
  11. Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherap… Co-author DOI 10.3892/ol.2017.5935↗
  12. Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant … Co-author DOI 10.3892/ol.2017.6220↗
  13. Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemoth… First author DOI 10.3892/ol.2017.6295↗
  14. Duodenal stenting followed by systemic chemotherapy for patients with pancreatic cancer and gastric outlet obstruction. Co-author DOI 10.1016/j.pan.2016.07.007↗
  15. Locked Nucleic Acid In Situ Hybridization Analysis of MicroRNA-21 Predicts Clinical Outcome in Patients After Resection for Pancreatic Cancer Treated with Adju… Co-author PMID 26977002↗
  16. The Surgical Apgar Score Is an Independent Prognostic Factor in Patients with Pancreatic Cancer Undergoing Pancreatoduodenectomy Followed by Adjuvant Chemother… Co-author PMID 27127164↗
  17. [Safety and Feasibility of Pancreatic Surgery for Pancreatic Cancer in Elderly Patients]. Co-author PMID 28133043↗
  18. Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients. Co-author DOI 10.1007/s00280-015-2736-5↗
  19. Potential prognostic significance of a new proteomic profile in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2015.07.003↗
  20. Impact of postoperative complications on survival and recurrence in pancreatic cancer. Co-author PMID 25862906↗
  21. Clinical implication of peritoneal cytology in the pancreatic cancer patients who underwent curative resection followed by adjuvant gemcitabine or S-1 chemothe… Co-author PMID 25911897↗
  22. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemci… Co-author PMID 25916085↗
  23. Glasgow Prognostic Score Predicts Clinical Outcomes in Patients with Pancreatic Cancer Undergoing Adjuvant Gemcitabine Monotherapy After Curative Surgery. Co-author PMID 26254380↗
  24. [The Safety and Feasibility of Conversion Surgery for Initially Unresectable Pancreatic Cancer]. First author PMID 26805070↗
  25. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer. Co-author DOI 10.1007/s00280-014-2601-y↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Soichiro Morinaga · 25 shared papers, 2014–2025 · strength 1.85
  2. Masaaki Murakawa · 23 shared papers, 2014–2025 · strength 1.75
  3. Makoto Ueno · 21 shared papers, 2014–2025 · strength 1.62
  4. Satoshi Kobayashi · 16 shared papers, 2014–2025 · strength 1.33
  5. Naoto Yamamoto · 15 shared papers, 2014–2025 · strength 1.28
  6. Manabu Morimoto · 20 shared papers, 2014–2020 · strength 1.18
  7. Takashi Oshima · 12 shared papers, 2015–2024 · strength 0.91
  8. Yuto Kamioka · 4 shared papers, 2020–2025 · strength 0.63
  9. Hiroshi Tamagawa · 6 shared papers, 2018–2024 · strength 0.60
  10. Shinnosuke Kawahara · 3 shared papers, 2024–2025 · strength 0.54
  11. Mariko Kamiya · 5 shared papers, 2018–2024 · strength 0.51
  12. Yohei Miyagi · 6 shared papers, 2016–2025 · strength 0.51
  13. Masakatsu Numata · 4 shared papers, 2018–2020 · strength 0.34
  14. Kota Washimi · 1 shared paper, 2025 · strength 0.20
  15. Yukihiko Hiroshima · 1 shared paper, 2025 · strength 0.20
  16. Robert M. Hoffman · 1 shared paper, 2025 · strength 0.20
  17. Shinichi Ohkawa · 3 shared papers, 2014–2016 · strength 0.14
  18. Hideki Taniguchi · 1 shared paper, 2018 · strength 0.08
  19. Shun Tezuka · 1 shared paper, 2016 · strength 0.05
  20. Makoto Akaike · 1 shared paper, 2014 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.